Toutes les études
Actif, mais pas en recrutementPHASE1INTERVENTIONNEL

A Study to Evaluate the Safety, Tolerability, and Effects on Blood and Urine Markers of Single Ascending Dose of GSK4771261 in Healthy Participants and Participants With Autosomal Dominant Polycystic Kidney Disease

This study is testing a new medication called GSK4771261. It's a 'Phase 1' study, which means it's one of the first steps in checking if a new drug is safe and how it works in people. No one, not even the doctors or participants, will know who is getting the new drug or a dummy pill. The study has two main parts. Part A involves healthy volunteers to see if the new drug is safe and how their bodies react to it. Part B is similar but focuses on people who have a type of kidney disease called autosomal dominant polycystic kidney disease (ADPKD). Researchers want to see if the drug affects their blood and urine markers.

En un coup d'œil

Statut
Actif, mais pas en recrutement
Phase
PHASE1
Sponsor
GlaxoSmithKline
Objectif d'inscription
86
Démarrer
11 Dec 2024
Achèvement estimé
23 Jul 2027

De quoi parle cette étude ?

This study is trying to understand more about a new medication called GSK4771261. Think of it as a very early stage of testing for a new drug. The main goals are to check if it's safe for people to take, how much of it stays in the body, and what effects it has on various measurements in your blood and urine.

The study is split into two groups. The first group, called Part A, involves healthy volunteers. This helps researchers understand the basic safety of the drug and how it works in bodies that aren't already affected by illness. The second group, Part B, will include people who have a specific inherited kidney condition called autosomal dominant polycystic kidney disease (ADPKD). By studying people with ADPKD, the researchers hope to learn if this new drug could potentially help manage or treat this condition.

It's important to know that this is a 'blinded' study. This means neither you, nor the study doctors, will know whether you are receiving the new drug or a 'placebo' – which looks identical but contains no active medicine. This helps make sure the study results are fair and unbiased. The findings from this study will help decide if this new drug should be tested further in larger studies.

Points clés

  • This study is testing a brand-new drug, GSK4771261, for safety and its effects.
  • It involves both healthy people (Part A) and those with ADPKD (Part B).
  • No one will know if they are receiving the drug or a 'dummy' pill.
  • The study checks blood and urine changes as well as general safety.
  • It's an early-stage 'Phase 1' study for potential future ADPKD treatment.

Qui peut être éligible ?

To join this study, you generally need to be a man or a woman aged between 25 and 65 years old. You also need to weigh at least 45 kilograms (about 7 stone 1 pound) and have a healthy body mass index (BMI) between 19.5 and 32. All participants must be able to understand the study and agree to take part by signing a consent form.

For Part A, you must be a healthy adult with no major ongoing health problems, as assessed by the study doctor. For women, you must have gone through menopause, had a hysterectomy or fallopian tubes tied, or have other reasons why you can't have children.

If you have Autosomal Dominant Polycystic Kidney Disease (ADPKD) and are interested in Part B, you must have a confirmed diagnosis of this condition. While you might have some health issues related to ADPKD, you should otherwise be in good general health. Your kidney function, measured by something called eGFR, needs to be reasonably good (at least 45 mL/min/1.73m²), and your doctor shouldn't expect it to get much worse quickly. You'll also need to have certain types of ADPKD based on imaging scans and a confirmed genetic fault related to the condition.

Cet étude pourrait-elle vous convenir ?

Répondez à ces questions rapides pour voir si vous êtes éligible. Ceci est un guide uniquement — l'équipe de recherche prend la décision finale.

  1. Are you between 25 and 65 years old?
  2. Do you weigh at least 45 kilograms (about 7 stone 1 pound)?
  3. Is your Body Mass Index (BMI) between 19.5 and 32?
  4. For women, are you unable to have children (e.g., post-menopause, sterilised)?
  5. For Part B, do you have a confirmed diagnosis of ADPKD?
Répondez à chaque question pour voir votre résultat.

En quoi consiste la participation ?

If you decide to take part in this study, you will be given either the new drug, GSK4771261, or a 'dummy' pill (placebo) that looks exactly the same. No one involved will know which you are receiving. You will need to come for several visits to the study clinic where doctors will check your health, take blood and urine samples, and monitor how your body is reacting to the treatment. They'll also perform other tests like physical exams and heart checks. The study length isn't specified, but Phase 1 studies often involve regular visits over weeks or months, followed by a period where researchers continue to check on your health. You will be told the exact schedule of visits and tests during the consent process.

Risques et avantages potentiels

Participating in a clinical trial like this could offer potential benefits, such as contributing to scientific understanding about ADPKD and potentially gaining early access to a new treatment, though there's no guarantee the treatment will directly benefit you. However, there are also potential risks involved, mainly from the new drug itself, which might cause side effects that we don't fully know about yet. You might also experience discomfort from blood tests and other procedures. It's really important to remember that you can stop participating in the study at any time, for any reason, without it affecting your usual medical care.

Locations (23)

  • GSK Investigational Site
    Code postal vérifié
    Rochester, États-Unis
  • GSK Investigational Site
    Code postal vérifié
    Bruxelles, Belgique
  • GSK Investigational Site
    Code postal vérifié
    Gand, Belgique
  • GSK Investigational Site
    Code postal vérifié
    Leuven, Belgium
  • GSK Investigational Site
    Code postal vérifié
    Londres, Canada
  • GSK Investigational Site
    Code postal vérifié
    Toronto, Canada
  • GSK Investigational Site
    Code postal vérifié
    Montréal, Canada
  • GSK Investigational Site
    Code postal vérifié
    Brest, France
  • GSK Investigational Site
    Code postal vérifié
    Paris, France
  • GSK Investigational Site
    Code postal vérifié
    Cologne, Allemagne
  • GSK Investigational Site
    Code postal vérifié
    Lübeck, Allemagne
  • GSK Investigational Site
    Code postal vérifié
    Groningen, Netherlands

Questions fréquentes

What is Autosomal Dominant Polycystic Kidney Disease (ADPKD)?

ADPKD is an inherited kidney condition where cysts (fluid-filled sacs) grow in the kidneys, which can cause them to become very large and affect how well they work.

Qu'est-ce qu'une étude de 'Phase 1' ?

Phase 1 is the earliest stage of human testing for a new drug. It mainly checks if the drug is safe, what dose is best, and how the body handles it.

What does 'blinded' mean in this study?

Being 'blinded' means neither you nor the study doctors will know if you are receiving the new drug or a dummy pill (placebo). This helps make the study fair.

Will I know if the new drug is working for me?

Because this is an early-stage study and it's 'blinded,' you won't know if you're getting the active drug or a placebo during the study. The main focus is on safety and how your body reacts.

Puis-je arrêter de participer à l'étude si je change d'avis ?

Yes, absolutely. You are free to withdraw from the study at any time, for any reason, without it affecting your normal medical care.

Comment en savoir plus

Parlez toujours à votre médecin généraliste ou spécialiste avant de décider de participer à une étude.

Discussion

Discussion communautaire

Propulsé par notre forum à community.patient.info. Veuillez être respectueux — ceci n'est pas un avis médical.